nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2013-17-4-44-48nefr-461Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESРОЛЬ РЕЦЕПТОРОВ, АКТИВИРУЮЩИХ ПРОЛИФЕРАЦИЮ ПЕРОКСИСОМ, В ФИЗИОЛОГИИ И ПАТОЛОГИИ ПОЧЕКPEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN KIDNEY PHYSIOLOGY AND PATHOLOGYРасинМ. С.RasinM. S.

Кафедра внутренней медицины № 3

БорзыхО. А.BorzykhO. A.

Кафедра внутренней медицины № 3

36000, г. Полтава, ул. Шевченко, д. 23. Тел. +380532676269, факс: +380532595887, моб. +380503047311

oksana.borzykh@rambler.ruМормольИ. А.Mormol’I. A.

Кафедра внутренней медицины № 3

Украинская медицинская стоматологическая академияUkraine2013100420131744448Copyright © Расин М.С., Борзых О.А., Мормоль И.А., 20132013Расин М.С., Борзых О.А., Мормоль И.А.Rasin M.S., Borzykh O.A., Mormol’ I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/461

Рецепторы, активирующие пролиферацию пероксисом (PPAR), ядерные транскрипционные факторы из семейства гормональных рецепторов, осуществляют контроль над углеводным и жировым обменом, энергетическим гомеостазом, активностью иммунной системы, воспалением и состоянием эндотелия сосудов. Все три типа PPAR экспрессированы в почках и играют важную роль в физиологии и патологии этих органов, выполняя протективную, противовоспалительную и антипролиферативную функцию при диабетической нефропатии, гломерулонефрите и остром повреждении почек.

Peroxisome proliferator-activated receptors (PPAR), nuclear transcription factors from family of hormonal receptors, carry out control above a carbohydrate and fatty acid metabolism, energy homeostasis, activity of the immune system, inflammation and endothelia of vessels. All of three types of PPAR‘s are expressed in kidney and play an important role in physiology and pathology of these organs, executing renoprotective action by inflammation, diabetes mellitus nephropathy, acute renal failure, glomerulonephritis and other damages.

рецепторы PPARфизиология и патология почекreceptors PPARkidney physiology and pathologyReferencesРасин АМ, Кайдашев ИП, Расин МС. Пероксисом пролифератор-активирующие рецепторы и их роль в системном воспалении, атерогенезе, артериальной гипертензии и хроническом обструктивном заболевании легких (обзор литературы). Український терапевтичний журн 2006;(2):100-108Расин АМ, Кайдашев ИП, Расин МС. Пероксисом пролифератор-активирующие рецепторы и их роль в системном воспалении, атерогенезе, артериальной гипертензии и хроническом обструктивном заболевании легких (обзор литературы). Український терапевтичний журн 2006;(2):100-108Fan Y, Wang Y, Tang Z. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28(2): 315–321Fan Y, Wang Y, Tang Z. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28(2): 315–321Расін ОМ, Кайдашев ИП, Расин МС. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPAR-γ. Міжнародний ендокринологічний журн 2007; 6(12): 71-76Расін ОМ, Кайдашев ИП, Расин МС. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPAR-γ. Міжнародний ендокринологічний журн 2007; 6(12): 71-76Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–874Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–874Letavernier E, Perez J, Joye E, et al. Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure. Journal of the American Society of Nephrology 2005; 16(8): 2395–2402Letavernier E, Perez J, Joye E, et al. Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure. Journal of the American Society of Nephrology 2005; 16(8): 2395–2402Rodríguez-Calvo R, Serrano L, Coll T, et al. Activation of peroxisome proliferator-activated receptor β/δ inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-κB activity via extracellular signal-related kinase 1/2. Diabetes 2008; 57(8): 2149–2157Rodríguez-Calvo R, Serrano L, Coll T, et al. Activation of peroxisome proliferator-activated receptor β/δ inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-κB activity via extracellular signal-related kinase 1/2. Diabetes 2008; 57(8): 2149–2157Lepenies J, Hewison M, Stewart PM, Quinkler M. Renal PPARγ mRNA expression increases with impairment of renal function in patients with chronic kidney disease. Nephrology 2010; 15(7): 683–691Lepenies J, Hewison M, Stewart PM, Quinkler M. Renal PPARγ mRNA expression increases with impairment of renal function in patients with chronic kidney disease. Nephrology 2010; 15(7): 683–691Chung BH, Lim SW, Ahn KO, et al. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology 2005; 10[Suppl 2]: 40–43Chung BH, Lim SW, Ahn KO, et al. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology 2005; 10[Suppl 2]: 40–43Cuzzocrea S. Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury. Vascular Pharmacology 2004; 41(6): 187–195Cuzzocrea S. Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury. Vascular Pharmacology 2004; 41(6): 187–195Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–688Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–688Li AC, Binder CJ, Gutierrez A et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004;114(11): 1564-1576Li AC, Binder CJ, Gutierrez A et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004;114(11): 1564-1576Zandbergen F, Plutzky J. PPAR-alpha in atherosclerosis and inflammation. Biochim Biophys Acta 2007; 1771(8): 972-82Zandbergen F, Plutzky J. PPAR-alpha in atherosclerosis and inflammation. Biochim Biophys Acta 2007; 1771(8): 972-82Portilla D, Dai G, Peters JM, et al. Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol 2000; 278(4): 667–675Portilla D, Dai G, Peters JM, et al. Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol 2000; 278(4): 667–675Kamijo Y, Hora K, Tanaka N, et al. Identification of functions of peroxisome proliferator-activated receptor α in proximal tubules. J Am Society of Nephrol 2002; 13(7): 1691–1702Kamijo Y, Hora K, Tanaka N, et al. Identification of functions of peroxisome proliferator-activated receptor α in proximal tubules. J Am Society of Nephrol 2002; 13(7): 1691–1702Thomas MC, Jandeleit-Dahm KA, Tikellis C. The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes. PPAR Res 2012; 2012: 456-529Thomas MC, Jandeleit-Dahm KA, Tikellis C. The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes. PPAR Res 2012; 2012: 456-529Sugden MC, Bulmer K, Gibbons GF, Holness MJ. Role of peroxisome proliferator-activated receptor-α in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding. Archives of Biochemistry and Biophysics 2001; 395(2): 246–252Sugden MC, Bulmer K, Gibbons GF, Holness MJ. Role of peroxisome proliferator-activated receptor-α in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding. Archives of Biochemistry and Biophysics 2001; 395(2): 246–252Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Arch Intern Med 2011; 172(10): 761-769. doi:10.1001/ archinternmed.2011.2230.Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Arch Intern Med 2011; 172(10): 761-769. doi:10.1001/ archinternmed.2011.2230.Czekalski S. Microalbuminuria as a reversible marker of kidney and vascular damage. Nefrologia i Dializoterapia Polska 2006; 10(4): 166–168Czekalski S. Microalbuminuria as a reversible marker of kidney and vascular damage. Nefrologia i Dializoterapia Polska 2006; 10(4): 166–168Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59(1): 260–269Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59(1): 260–269Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005; 366(9500): 1849–1861Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005; 366(9500): 1849–1861Park CW, Zhang Y, Zhang X, et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mic. Kidney Int 2006; 69(9): 1511–1517Park CW, Zhang Y, Zhang X, et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mic. Kidney Int 2006; 69(9): 1511–1517Wilmer W. PPAR-α ligands inhibit H2O2-mediated activation of transforming growth factor-β1 in human mesangial cells. Antioxidants & Redox Signaling 2002; 4(6): 877–884Wilmer W. PPAR-α ligands inhibit H2O2-mediated activation of transforming growth factor-β1 in human mesangial cells. Antioxidants & Redox Signaling 2002; 4(6): 877–884Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Experimental Biology and Medicine 2010; 235(3): 383–391Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Experimental Biology and Medicine 2010; 235(3): 383–391Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacology & Therapeutics 2009; 122(3): 246–263Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacology & Therapeutics 2009; 122(3): 246–263Pollex RL, Mamakeesick M, Zinman B, et al. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Journal of Diabetes and Its Complications 2007; 21(3): 166–171Pollex RL, Mamakeesick M, Zinman B, et al. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Journal of Diabetes and Its Complications 2007; 21(3): 166–171Li S, Bhatt R, Megyesi J, et al. PPAR-α ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. American Journal of Physiology 2004; 287(5): 990–998Li S, Bhatt R, Megyesi J, et al. PPAR-α ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. American Journal of Physiology 2004; 287(5): 990–998Lehmann JM. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem 1995; 270: 12953-12956Lehmann JM. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem 1995; 270: 12953-12956Li Andrew C, Christopher K. Glass PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. Journal of Lipid Research 2010; (45): 2161-2173Li Andrew C, Christopher K. Glass PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. Journal of Lipid Research 2010; (45): 2161-2173Ohshima K, Masaki M, Masatsugu H. Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation. Journal of International Vascular Medicine 2012; Internet resource. v. 2012.Ohshima K, Masaki M, Masatsugu H. Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation. Journal of International Vascular Medicine 2012; Internet resource. v. 2012.Кайдашев ИП. NF-kB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза. Международный эндокринологический журн 2011; 3(35): 35-40Кайдашев ИП. NF-kB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза. Международный эндокринологический журн 2011; 3(35): 35-40Кайдашев ІП, Расін ОМ, Микитюк МВ, Расін МС. Аторвастатин та розиглітазон індукують апоптоз моноцитів/макрофагів крові: роль поліморфізму гена PPARγ. Ліки 2007; 4: 55Кайдашев ІП, Расін ОМ, Микитюк МВ, Расін МС. Аторвастатин та розиглітазон індукують апоптоз моноцитів/макрофагів крові: роль поліморфізму гена PPARγ. Ліки 2007; 4: 55Bishop-Bailey D, Bystrom O. Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacology & Therapeutics 2009; 124: 141–150Bishop-Bailey D, Bystrom O. Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacology & Therapeutics 2009; 124: 141–150Ko GJ, Kang YS, Han SY, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008; 23(9): 2750–2760Ko GJ, Kang YS, Han SY, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008; 23(9): 2750–2760Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. American Journal of Physiology 2007; 292(4): 1141–1150Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. American Journal of Physiology 2007; 292(4): 1141–1150Kiss-Tóth E, Tamás R. PPARγ in Kidney Physiology and Pathophysiology. PPAR Res 2008; 2008: 183108. doi: 10.1155/2008/183108.Kiss-Tóth E, Tamás R. PPARγ in Kidney Physiology and Pathophysiology. PPAR Res 2008; 2008: 183108. doi: 10.1155/2008/183108.Calkin AC. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006; 21(9): 2399–2405Calkin AC. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006; 21(9): 2399–2405Yang H-C, Ma L-J, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69(10): 1756–1764Yang H-C, Ma L-J, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69(10): 1756–1764Hong G, Lockhart A, Davis B, et al. PPARγ activation enhances cell surface ENaCα via up-regulation of SGK1 in human collecting duct cells. The FASEB Journal 2003; 17(13): 1966–1968Hong G, Lockhart A, Davis B, et al. PPARγ activation enhances cell surface ENaCα via up-regulation of SGK1 in human collecting duct cells. The FASEB Journal 2003; 17(13): 1966–1968Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. The American Journal of Pathology 1936; 12(1): 83–98Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. The American Journal of Pathology 1936; 12(1): 83–98Takai S, Jin D, Kimura M, et al. Inhibition of vascular angiotensin-coverting enzyme by telmisartan via the peroxisome proliferator-activated receptor γ agonistic property in rats. Hypertension Research 2007; 30(12): 1231–1237Takai S, Jin D, Kimura M, et al. Inhibition of vascular angiotensin-coverting enzyme by telmisartan via the peroxisome proliferator-activated receptor γ agonistic property in rats. Hypertension Research 2007; 30(12): 1231–1237Lee, CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic in ammation: modulation by PPAR-delta. Science 2003; 302(5644): 453-457Lee, CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic in ammation: modulation by PPAR-delta. Science 2003; 302(5644): 453-457Takata Y, Liu J, Yin I. PPAR-delta mediated antiin ammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A 2008; 105(11):4277-4282Takata Y, Liu J, Yin I. PPAR-delta mediated antiin ammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A 2008; 105(11):4277-4282Collino M. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radical Biology and Medicine 2011; 50 (issue 2): 345-353Collino M. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radical Biology and Medicine 2011; 50 (issue 2): 345-353

The authors declare that there are no conflicts of interest present.